MX2019010461A - Plataforma de identificacion de peptidos inmunogenicos personalizada. - Google Patents
Plataforma de identificacion de peptidos inmunogenicos personalizada.Info
- Publication number
- MX2019010461A MX2019010461A MX2019010461A MX2019010461A MX2019010461A MX 2019010461 A MX2019010461 A MX 2019010461A MX 2019010461 A MX2019010461 A MX 2019010461A MX 2019010461 A MX2019010461 A MX 2019010461A MX 2019010461 A MX2019010461 A MX 2019010461A
- Authority
- MX
- Mexico
- Prior art keywords
- personalised
- methods
- immunogenic peptide
- polypeptide
- identification platform
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 230000002163 immunogen Effects 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
- G16B15/30—Drug targeting using structural data; Docking or binding prediction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/605—MHC molecules or ligands thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
La descripción se refiere a métodos para identificar fragmentos de un polipéptido que son inmunogénicos para un sujeto humano específico, métodos para preparar composiciones farmacéuticas personalizadas que comprenden dichos fragmentos de polipéptido, composiciones farmacéuticas específicas para un sujeto humano que comprenden dichos fragmentos de polipéptido y métodos de tratamiento que utilizan dichas composiciones. Los métodos comprenden identificar un fragmento del polipéptido que se une a múltiples HLA del sujeto.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17159242.1A EP3369431A1 (en) | 2017-03-03 | 2017-03-03 | Vaccine |
EP17159243.9A EP3370065A1 (en) | 2017-03-03 | 2017-03-03 | Immunogenic peptides |
GBGB1703809.2A GB201703809D0 (en) | 2017-03-09 | 2017-03-09 | Vaccine |
PCT/EP2018/055231 WO2018158456A1 (en) | 2017-03-03 | 2018-03-02 | Personalised immunogenic peptide identification platform |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019010461A true MX2019010461A (es) | 2020-01-09 |
Family
ID=61386864
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019010461A MX2019010461A (es) | 2017-03-03 | 2018-03-02 | Plataforma de identificacion de peptidos inmunogenicos personalizada. |
MX2019010460A MX2019010460A (es) | 2017-03-03 | 2018-03-02 | Plataforma de identificacion de peptidos inmunogenicos basada en poblacion. |
MX2019010459A MX2019010459A (es) | 2017-03-03 | 2018-03-02 | Vacuna. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019010460A MX2019010460A (es) | 2017-03-03 | 2018-03-02 | Plataforma de identificacion de peptidos inmunogenicos basada en poblacion. |
MX2019010459A MX2019010459A (es) | 2017-03-03 | 2018-03-02 | Vacuna. |
Country Status (16)
Country | Link |
---|---|
US (9) | US10213497B2 (es) |
EP (3) | EP3589954A1 (es) |
JP (4) | JP7437939B2 (es) |
KR (3) | KR20190133177A (es) |
CN (3) | CN110651188B (es) |
AU (3) | AU2018226566A1 (es) |
BR (3) | BR112019018313A2 (es) |
CA (3) | CA3054861A1 (es) |
CL (4) | CL2019002534A1 (es) |
CO (3) | CO2019010524A2 (es) |
IL (3) | IL268919B2 (es) |
MA (3) | MA47677A (es) |
MX (3) | MX2019010461A (es) |
SG (3) | SG11201907402SA (es) |
WO (3) | WO2018158457A1 (es) |
ZA (2) | ZA201904723B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016235388B2 (en) * | 2015-03-20 | 2022-02-03 | Children's National Medical Center | Generating virus or other antigen-specific T cells from a naive T cell population |
SG11201907402SA (en) | 2017-03-03 | 2019-09-27 | Treos Bio Zrt | Population-based immunogenic peptide identification platform |
KR20210086612A (ko) | 2018-09-04 | 2021-07-08 | 트레오스 바이오 리미티드 | 펩타이드 백신 |
GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
GB201814361D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
US11945850B2 (en) * | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
TW202039535A (zh) * | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
KR102159921B1 (ko) * | 2020-03-24 | 2020-09-25 | 주식회사 테라젠바이오 | 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
JP2023520562A (ja) | 2020-04-03 | 2023-05-17 | ペップティーシー ヴァクシーンズ リミテッド | コロナウイルスワクチン |
GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
BR112022012316A2 (pt) * | 2020-04-20 | 2022-11-16 | NEC Laboratories Europe GmbH | Método implementado por computador de selecionar uma ou mais sequências de aminoácidos para inclusão em uma vacina a partir de um conjunto de sequências de aminoácidos candidatas imunogênicas previstas; método de criação de uma vacina; sistema para selecionar uma ou mais sequências de aminoácidos para inclusão em uma vacina a partir de um conjunto de sequências de aminoácidos candidatas imunogênicas previstas; e; meio legível por computador |
CN112048001B (zh) * | 2020-09-08 | 2022-04-05 | 南方科技大学 | 一种肿瘤新生抗原多肽及其应用 |
KR102278727B1 (ko) * | 2020-09-16 | 2021-07-19 | 주식회사 테라젠바이오 | 대상 암 조직 및 세포 유리형 dna 유래 펩타이드 서열 및 hla 클래스 ii 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램 |
WO2023017768A1 (ja) | 2021-08-10 | 2023-02-16 | 日本電気株式会社 | 情報処理システム及び情報処理方法 |
TW202322137A (zh) | 2021-10-04 | 2023-06-01 | 日商日本電氣股份有限公司 | 管理方法、管理系統及電子健康紀錄系統 |
WO2023059606A1 (en) * | 2021-10-06 | 2023-04-13 | Cancervax, Inc. | Methods and compositions for cancer treatment |
WO2023211024A1 (ko) * | 2022-04-27 | 2023-11-02 | 포항공과대학교 산학협력단 | 시험관 진화 기반 핫스팟 유래 펩타이드-핵산 하이브리드 분자 제조방법 |
CN115785203B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标10及其用途 |
GB202216453D0 (en) | 2022-11-04 | 2022-12-21 | Lisziewicz Julianna | Identification of antigens which induce t-cell responses |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
ATE511849T1 (de) | 1996-03-11 | 2011-06-15 | Epimmune Inc | Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle |
US6617434B1 (en) | 1996-05-31 | 2003-09-09 | North Shore Long Island Jewish Research Institute | Identificiaton of differentially methylated and mutated nucleic acids |
US20030148463A1 (en) | 1997-04-14 | 2003-08-07 | Micromet Ag | Novel method for the production of anti-human antigen receptors and uses thereof |
KR100663319B1 (ko) * | 1997-04-14 | 2007-01-02 | 마이크로메트 에이지 | 인간 17-1에이항원에 대해 특이성을 갖는 인간항체 및 그용도 |
FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
US6673580B2 (en) | 2000-10-27 | 2004-01-06 | Genentech, Inc. | Identification and modification of immunodominant epitopes in polypeptides |
US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
MXPA05002455A (es) | 2002-09-06 | 2005-06-03 | Mannkind Corp | Secuencias de epitopes. |
GB0228900D0 (en) * | 2002-12-11 | 2003-01-15 | Ml Lab Plc | Cancer Immunotherapy |
WO2004092360A2 (en) | 2003-04-10 | 2004-10-28 | Chiron Corporation | The severe acute respiratory syndrome coronavirus |
US20050100883A1 (en) | 2003-11-12 | 2005-05-12 | Wang Chang Y. | Peptide-based diagnostic reagents for SARS |
JP4779067B2 (ja) | 2004-01-20 | 2011-09-21 | 愛知県 | HLA−A2402拘束性Ep−CAM特異的CTLが認識するエピトープ・ペプチド及びその用途 |
CA2566506A1 (en) | 2004-06-01 | 2005-12-15 | Innogenetics N.V. | Peptides for inducing a ctl and/or htl response to hepatitis c virus |
EP1842911A4 (en) | 2005-01-25 | 2008-12-10 | Nec Corp | HLA BINDING PEPTIDES, FOR THOSE CODING DNA FRAGMENTS AND RECOMBINANT VECTORS |
RU2396088C2 (ru) | 2005-02-04 | 2010-08-10 | СУРВАК АпС | Вакцина на основе пептидов сурвивина |
CN100402554C (zh) * | 2005-02-25 | 2008-07-16 | 李玉新 | 睾丸特异性蛋白50人源抗体的制备及用途 |
FR2891462B1 (fr) | 2005-09-30 | 2009-10-16 | Commissariat Energie Atomique | Epitopes t cd4+ de la survivine et leurs applications |
GB0520067D0 (en) | 2005-10-01 | 2005-11-09 | Cancer Rec Tech Ltd | Treatment of cancer |
US9487574B2 (en) | 2006-09-21 | 2016-11-08 | Vaxil Biotherapeutics Ltd. | Antigen specific multi epitope vaccines |
WO2008039874A2 (en) | 2006-09-26 | 2008-04-03 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
EP2042600A1 (en) | 2007-09-28 | 2009-04-01 | Commissariat A L'energie Atomique | A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications |
JP5546448B2 (ja) | 2008-03-31 | 2014-07-09 | 株式会社バイオイミュランス | MHCクラスII分子に提示されるサーバイビン(Survivin)の部分ペプチドとその利用法 |
DK2119726T5 (en) | 2008-05-14 | 2018-03-26 | Immatics Biotechnologies Gmbh | Novel and powerful MHC class II peptides derived from survivin and neurocan |
TW201008574A (en) * | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
GB0818065D0 (en) * | 2008-10-02 | 2008-11-05 | Cancer Rec Tech Ltd | Immunogenic peptides and uses thereof |
US20120244145A1 (en) * | 2009-11-16 | 2012-09-27 | Duke University | Enhanced immunological responses |
GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
US20170039314A1 (en) * | 2010-03-23 | 2017-02-09 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
WO2012051282A2 (en) | 2010-10-14 | 2012-04-19 | The Ohio State University Research Foundation | Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy |
EP2745845A1 (en) * | 2012-12-19 | 2014-06-25 | Centre Hospitalier Universitaire de Bordeaux | A method for preventing or treating an HIV infection |
WO2014180490A1 (en) * | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and cancer drugs |
US9884895B2 (en) | 2014-03-20 | 2018-02-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for chimeric coronavirus spike proteins |
WO2015164798A1 (en) | 2014-04-25 | 2015-10-29 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
AU2015314776A1 (en) | 2014-09-14 | 2017-04-06 | Washington University | Personalized cancer vaccines and methods therefor |
EP3227679A1 (en) * | 2014-12-03 | 2017-10-11 | Verik Bio, Inc. | Identification, selection and use of high curative potential t cell epitopes |
JP7236216B2 (ja) * | 2015-04-23 | 2023-03-09 | ナントミクス,エルエルシー | がんのネオエピトープ |
US11090332B2 (en) | 2015-05-21 | 2021-08-17 | Regen BioPharma, Inc. | Antigen specific mRNA cellular cancer vaccines |
JP2018532736A (ja) * | 2015-10-12 | 2018-11-08 | ナントミクス,エルエルシー | チェックポイント阻害物質への感受性を予測するmsiおよびネオエピトープの探索のための系、組成物、および方法 |
GB201604755D0 (en) | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
US11684657B2 (en) | 2016-10-07 | 2023-06-27 | Board Of Regents, The University Of Texas System | HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subject |
TWI796314B (zh) | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 |
EP3369431A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Vaccine |
EP3370065A1 (en) | 2017-03-03 | 2018-09-05 | Treos Bio Kft | Immunogenic peptides |
SG11201907402SA (en) | 2017-03-03 | 2019-09-27 | Treos Bio Zrt | Population-based immunogenic peptide identification platform |
EP3731876A4 (en) | 2017-12-28 | 2022-04-06 | Gritstone bio, Inc. | ANTIGEN-BINDING PROTEINS DIRECTED AGAINST COMMON ANTIGENS |
US20210213066A1 (en) | 2018-05-18 | 2021-07-15 | Children's National Medical Center | Improved cell therapy compositions for hematopoietic stem cell transplant patients |
EP3796923A4 (en) | 2018-05-18 | 2022-03-09 | Children's National Medical Center | IMPROVED TARGETED T-CELL THERAPY |
GB201814361D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Immunogenetic cancer screening test |
GB201814362D0 (en) | 2018-09-04 | 2018-10-17 | Treos Bio Zrt | Composition and process for preparing vaccine |
KR20210086612A (ko) | 2018-09-04 | 2021-07-08 | 트레오스 바이오 리미티드 | 펩타이드 백신 |
EP3908293A4 (en) | 2019-01-07 | 2023-01-11 | Children's National Medical Center | EX VIVO ACTIVATED T-LYMPHOCYTIC COMPOSITIONS AND METHODS OF USE THEREOF |
US20220062342A1 (en) | 2019-01-07 | 2022-03-03 | Children's National Medical Center | Improved targeted t-cell therapy for treatment of multiple myeloma |
GB202004974D0 (en) | 2020-04-03 | 2020-05-20 | Treos Bio Ltd | Coronavirus vaccine |
-
2018
- 2018-03-02 SG SG11201907402SA patent/SG11201907402SA/en unknown
- 2018-03-02 AU AU2018226566A patent/AU2018226566A1/en active Pending
- 2018-03-02 JP JP2019568816A patent/JP7437939B2/ja active Active
- 2018-03-02 BR BR112019018313A patent/BR112019018313A2/pt unknown
- 2018-03-02 US US15/910,988 patent/US10213497B2/en active Active
- 2018-03-02 WO PCT/EP2018/055232 patent/WO2018158457A1/en unknown
- 2018-03-02 MA MA047677A patent/MA47677A/fr unknown
- 2018-03-02 KR KR1020197029093A patent/KR20190133177A/ko not_active Application Discontinuation
- 2018-03-02 KR KR1020197029092A patent/KR102549625B1/ko active IP Right Grant
- 2018-03-02 IL IL268919A patent/IL268919B2/en unknown
- 2018-03-02 BR BR112019018307-8A patent/BR112019018307A2/pt unknown
- 2018-03-02 EP EP18707724.3A patent/EP3589954A1/en active Pending
- 2018-03-02 AU AU2018228786A patent/AU2018228786A1/en active Pending
- 2018-03-02 US US15/910,965 patent/US20180264095A1/en not_active Abandoned
- 2018-03-02 CN CN201880014727.1A patent/CN110651188B/zh active Active
- 2018-03-02 MA MA047678A patent/MA47678A/fr unknown
- 2018-03-02 SG SG11201907524UA patent/SG11201907524UA/en unknown
- 2018-03-02 CA CA3054861A patent/CA3054861A1/en active Pending
- 2018-03-02 EP EP18710392.4A patent/EP3589951A1/en active Pending
- 2018-03-02 MX MX2019010461A patent/MX2019010461A/es unknown
- 2018-03-02 CA CA3054866A patent/CA3054866A1/en active Pending
- 2018-03-02 SG SG11201906765UA patent/SG11201906765UA/en unknown
- 2018-03-02 WO PCT/EP2018/055231 patent/WO2018158456A1/en unknown
- 2018-03-02 EP EP18707725.0A patent/EP3589310A1/en active Pending
- 2018-03-02 US US15/910,930 patent/US20180264094A1/en not_active Abandoned
- 2018-03-02 WO PCT/EP2018/055230 patent/WO2018158455A1/en unknown
- 2018-03-02 JP JP2019568815A patent/JP2020510698A/ja active Pending
- 2018-03-02 CA CA3054871A patent/CA3054871A1/en active Pending
- 2018-03-02 CN CN201880014745.XA patent/CN110651189A/zh active Pending
- 2018-03-02 MA MA047683A patent/MA47683A/fr unknown
- 2018-03-02 BR BR112019018312-4A patent/BR112019018312A2/pt unknown
- 2018-03-02 MX MX2019010460A patent/MX2019010460A/es unknown
- 2018-03-02 KR KR1020197029094A patent/KR102591136B1/ko active IP Right Grant
- 2018-03-02 CN CN201880014739.4A patent/CN110621334A/zh active Pending
- 2018-03-02 MX MX2019010459A patent/MX2019010459A/es unknown
- 2018-03-02 AU AU2018228785A patent/AU2018228785A1/en active Pending
- 2018-03-02 JP JP2019568814A patent/JP2020514413A/ja active Pending
-
2019
- 2019-01-10 US US16/244,497 patent/US11213578B2/en active Active
- 2019-07-18 ZA ZA2019/04723A patent/ZA201904723B/en unknown
- 2019-07-18 ZA ZA2019/04725A patent/ZA201904725B/en unknown
- 2019-08-26 IL IL268917A patent/IL268917B2/en unknown
- 2019-08-26 IL IL26892019A patent/IL268920A/en unknown
- 2019-09-03 CL CL2019002534A patent/CL2019002534A1/es unknown
- 2019-09-03 CL CL2019002532A patent/CL2019002532A1/es unknown
- 2019-09-03 CL CL2019002533A patent/CL2019002533A1/es unknown
- 2019-09-26 CO CONC2019/0010524A patent/CO2019010524A2/es unknown
- 2019-09-26 CO CONC2019/0010503A patent/CO2019010503A2/es unknown
- 2019-09-27 CO CONC2019/0010698A patent/CO2019010698A2/es unknown
-
2021
- 2021-09-17 US US17/448,020 patent/US20220031823A1/en active Pending
- 2021-11-09 US US17/454,225 patent/US20220072114A1/en active Pending
- 2021-12-22 US US17/645,737 patent/US11426452B2/en active Active
- 2021-12-22 US US17/645,741 patent/US11628211B2/en active Active
-
2022
- 2022-10-14 CL CL2022002836A patent/CL2022002836A1/es unknown
- 2022-12-09 JP JP2022197534A patent/JP2023051941A/ja active Pending
-
2023
- 2023-02-08 US US18/166,420 patent/US20230405100A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201904725B (en) | Personalised immunogenic peptide identification platform | |
MX2022005291A (es) | Vacunas para el tratamiento y prevencion del cancer. | |
BR112017017293A2 (pt) | método para predizer modificações de aminoácidos, para selecionar e/ou classificar modificações de aminoácidos e para fornecer uma vacina e vacina | |
PH12018500233A1 (en) | Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof | |
GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
MX2021005373A (es) | Variantes de proteinas de union al factor h y metodos de uso de estas. | |
WO2020131586A3 (en) | Methods for identifying neoantigens | |
MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
IL277632A (en) | CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses | |
WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
NZ728041A (en) | Substances and methods for the use in prevention and/or treatment in huntington’s disease | |
EA201992057A1 (ru) | Персонализированная платформа для идентификации иммуногенного пептида | |
ZA202201468B (en) | Method | |
EP3626260A4 (en) | PEPTIDIC VACCINE AND PEPTIDIC VACCINE COMPOSITION FOR CRANIAL NERVE DISEASE | |
WO2015168607A3 (en) | Ceacam5 peptides for crohn's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: TREOS BIO LIMITED |